C. Robert Horsburgh Jr, MD
Professor of Epidemiology
Boston University School of Public Health
Dept of Epidemiology

MD, Case Western Reserve University
MS, Yale University



Dr. Horsburgh has 30 years of experience in public health and medicine. He currently holds faculty positions in the Department of Biostatistics, the Department of GLobal Health and the Department of Medicine. Dr. Horsburgh teaches courses in the Epidemiology of AIDS and the Epidemiology of Tuberculosis. His research focuses on tuberculosis, nontuberculous mycobacterial infections and opportunistic infections in AIDS. Currently, he is involved in research in Brazil, India, Peru, South Africa and Tanzania. He has served as the National Steering Committee Co-Chairman of the Tuberculosis Trials Consortium and the Tuberculosis Epidemiologic Studies Consortium. He is currently the Chairman of the Steering Committee of RESIST-TB, an international organization dedicated to improving MDR-TB treatment through Clinical Trials (www.resisttb.org). His office is located in the Center for Global Health and Development at BU School of Public Health.

Professor
Boston University School of Public Health
Global Health


Professor
Boston University School of Medicine
Medicine
Infectious Diseases

Professor
Boston University School of Public Health
Biostatistics


Boston Medical Center



2015 International Union Against Tuberculosis and Lung Disease, North American Region: Lifetime Achievement Award
2011 Boston University School of Public Health: Faculty Career Award in Research and Scholarship
2011 CDC: Excellence in Public Health Impact Award


Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)
08/15/2017 - 07/31/2018 (PI)
NIH/National Institute of Allergy & Infe
1R01AI134430-01

Phase 2 Pharmacodynamic Study of High-dose Levofloxacin inMDR-TB Treatment
08/01/2016 - 07/31/2018 (PI)
NIH/National Institute of Allergy & Infe
4U01AI100805-04

Biomarkers and mechanisms of Paucibacillary and Latent Tuberculosis
08/01/2014 - 07/31/2018 (PI)
Boston Medical Center Corporation NIH NIAID
5U19AI111276-03

Lifespan/Tufts/brown Center for AIDS Research (CFAR): Core A, Core B, Core G and SWG1
07/01/2016 - 06/30/2018 (PI)
The Miriam Hospital NIH NIAID
4P30AI042853-19

The impact of Alcohol Consumption on TB Treatment Outcomes
04/08/2016 - 03/31/2018 (PI)
Boston Medical Center Corporation NIH NIAID
5R01AI119037-02

Tuberculosis Trials Consortium
10/01/2014 - 09/30/2017 (PI)
Veterans Affairs Medical Center of Washi HHS CDC


Biomarkers for Risk of TB and for TB Treatment Failure and Relapse
10/02/2013 - 09/15/2017 (PI)
Boston Medical Center Corporation National Science Fdn


Autophagy-based HDT for Tuberculosis
09/25/2015 - 08/31/2017 (PI)
University of New Mexico NIH NIAID
5UH2AI122313-02

Impact of Pregnancy on Tuberculosis
08/25/2015 - 07/31/2017 (PI)
Boston Medical Center Corporation NIH NIAID
R01AI124217-02

Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care
06/15/2012 - 05/31/2017 (PI)
Boston Medical Center Corporation NIH NIDA
5R01DA031059-03

Showing 10 of 24 results. Show All Results

BU Clinical HIV/AIDS Research Training Program
08/01/2016 - 07/31/2021 (PI)
NIH-NIAID
2T32AI052074-12

Lifespan/Tufts/brown Center for AIDS Research (CFAR): Core K Clinical Sciences Core
07/01/2016 - 06/30/2018 (PI)
Miriam Hospital NIH-NIAID

BU Clinical HIV/AIDS Research Training Program
08/02/2010 - 07/31/2016 (PI)
NIH-NIAID

Boston Community Partnership Against HIV
09/30/2002 - 09/29/2005 (PI)
DHHS-Office Minority Hlth

History Of Hepatitis C Infecti
09/30/1999 - 06/30/2005 (PI)
NIH-NIDDK



Yr Title Project-Sub Proj Pubs
2017 Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT) 1R01AI134430-01
2017 BU Clinical HIV/AIDS Research Training Program 5T32AI052074-12 27
2017 Clinical Core 5U19AI111276-04-7772 3
2016 Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment 4U01AI100805-04
2016 BU Clinical HIV/AIDS Research Training Program 2T32AI052074-11A1 27
2016 Biomarkers of Persistent TB Infection and TB Treatment Relapse 5U19AI111276-03-7767 3
2016 Clinical Core 5U19AI111276-03-7772 3
2015 Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment 5U01AI100805-03
2015 Biomarkers of Persistent TB Infection and TB Treatment Relapse 5U19AI111276-02-7767 3
2015 Clinical Core 5U19AI111276-02-7772 3
Showing 10 of 42 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Assoumou SA, Tasillo A, Leff JA, Schackman BR, Drainoni ML, Horsburgh CR, Barry MA, Regis C, Kim AY, Marshall A, Saxena S, Smith PC, Linas BP. Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. Clin Infect Dis. 2018 Jan 18; 66(3):376-384.View Related Profiles. PMID: 29020317.
     
  2. Rohr JK, Ive P, Horsburgh CR, Berhanu R, Hoffmann CJ, Wood R, Boulle A, Giddy J, Prozesky H, Vinikoor M, Mwanza MW, Wandeler G, Davies MA, Fox MP. Assessing the association between changing NRTIs when initiating second-line ART and treatment outcomes. J Acquir Immune Defic Syndr. 2017 Dec 04.View Related Profiles. PMID: 29206723.
     
  3. Tasillo A, Salomon JA, Trikalinos TA, Horsburgh CR, Marks SM, Linas BP. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model. JAMA Intern Med. 2017 Dec 01; 177(12):1755-1764.View Related Profiles. PMID: 29049814.
     
  4. Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials. 2017 Nov 25; 18(1):563. PMID: 29178937.
     
  5. Hochberg NS, Sarkar S, Horsburgh CR, Knudsen S, Pleskunas J, Sahu S, Kubiak RW, Govindarajan S, Salgame P, Lakshminarayanan S, Sivaprakasam A, White LF, Joseph NM, Ellner JJ, Roy G. Comorbidities in pulmonary tuberculosis cases in Puducherry and Tamil Nadu, India: Opportunities for intervention. PLoS One. 2017; 12(8):e0183195.View Related Profiles. PMID: 28832615.
     
  6. Van Ness SE, Chandra A, Sarkar S, Pleskunas J, Ellner JJ, Roy G, Lakshminarayanan S, Sahu S, Horsburgh CR, Jenkins HE, Hochberg NS. Predictors of delayed care seeking for tuberculosis in southern India: an observational study. BMC Infect Dis. 2017 Aug 15; 17(1):567.View Related Profiles. PMID: 28806911.
     
  7. Reddy D, Walker J, White LF, Brandeis GH, Russell ML, Horsburgh CR, Hochberg NS. Latent Tuberculosis Infection Testing Practices in Long-Term Care Facilities, Boston, Massachusetts. J Am Geriatr Soc. 2017 Jun; 65(6):1145-1151.View Related Profiles. PMID: 28467605.
     
  8. Simonsen DF, Farkas DK, Horsburgh CR, Thomsen RW, Sørensen HT. Increased risk of active tuberculosis after cancer diagnosis. J Infect. 2017 Jun; 74(6):590-598.View Related Profiles. PMID: 28366685; DOI: 10.1016/j.jinf.2017.03.012;.
     
  9. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017 Mar 15. PMID: 28344011; DOI: 10.1016/S2213-2600(17)30079-6;.
     
  10. Moro RN, Sterling TR, Saukkonen J, Vernon A, Horsburgh CR, Chaisson RE, Hamilton CD, Villarino ME, Goldberg S. Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. Int J Tuberc Lung Dis. 2017 Mar 01; 21(3):286-296.View Related Profiles. PMID: 28087928; DOI: 10.5588/ijtld.16.0469;.
     
Showing 10 of 198 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 198 publications over 37 distinct years, with a maximum of 14 publications in 2011

YearPublications
19811
19833
19842
19853
19865
19874
19884
19898
19903
19912
19927
19939
19945
19954
19965
19976
19982
19994
20006
20012
20024
20033
20043
20052
20069
20073
20086
20091
201011
201114
20128
20138
20148
201511
201611
201710
20181
Contact for Mentoring:


715 Albany St Talbot Building
Boston MA 02118
Google Map


Horsburgh's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department